drugset / Trial / NCT05252598

Mood and Cognitive Effects of Psilocybin in Healthy Participants

NCT05252598

RandomizedSingle-groupQuadruple-blindTreatment

Summary

This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects.

Timeline

Start
2023-01
Primary completion
2023-08
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 1 mg Oral
Subject Psilocybin Other / unclassified 2 mg Oral
Subject Psilocybin Other / unclassified 5 mg Oral
Subject Psilocybin Other / unclassified 8 mg Oral
Subject Psilocybin Other / unclassified 10 mg Oral